Cover Image
市場調查報告書

全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年)

Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 353905
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年) Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

全球大腸癌症診斷、治療藥市場,預計2015年∼2020年以1∼5%的年複合成長率成長。

本報告提供全球大腸癌症診斷、治療藥市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等,有系統的資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 波特的五力分析

第5章 市場區隔

  • 各診斷
  • 各治療
  • 各地區

第6章 競爭情形

  • M&A
  • 契約、夥伴關係、聯盟
  • 新產品的銷售
  • 建議

第7章 企業簡介

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomic
  • Companion Dx
  • EDP Biotech
  • Epigenomics AG
  • Exact Sciences
  • FUJIREBIO
  • Genomic Tree
  • Metabiomics
  • Oncocyte (Biotime)
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • Volition Rx

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The global cervical cancer market was valued at USD 2,140 million in 2015 and is expected to grow at a CAGR of 2-5% during the period from 2015 to 2021.

Cervical cancer is generally characterized by the abnormal growth of cancerous cells in the tissues of the cervix, and it may manifest itself as a squamous-cell carcinoma or adenocarcinoma. According to the World Health Organization (WHO), cervical cancer accounts for the death of more than 270,000 women annually, primarily in the developing countries. With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing, and colposcopy for early detection, the market is highly competitive with a high growth rate.

Global Cervical Cancer Diagnostics and Therapeutics Market-Market Dynamics

The advent of technologically advanced computer-guided screening tests for cervical cancer in order to reduce the rate of false-negative results and improved accuracy are expected to contribute to the growth of the cervical cancer diagnostic tests market during the forecast period, from 2014 to 2021.

Drivers

Some factors contributing to the growth of the market are:

Rising prevalence of cervical cancer

Favorable government initiatives

Funding to increase disease awareness

Increase of pipeline cervical cancer screening tests

Aging population

Increasing consumer awareness

Restraints

Some factors limiting the growth of the market are:

Cost of screening tests

Availability of HPV vaccines

Uncertain reimbursement rates

Changes in regulatory guidelines

The global cervical cancer diagnostic and therapeutic market is segmented on the basis of diagnostics test (Pap smear test, HPV testing, colposcopy, cervical cancer biopsy), methods (molecular method, cytopathological method, physical method), end-users (hospitals, laboratories, independent physicians, clinics, and others), therapies (surgery, radiation therapy, chemotherapy and others) and geography (North America, Asia-Pacific, Europe, Middle East & Africa and Latin America). North America is expected to account for almost 49% of the total market share by 2020.

Some of the key players in the market are:

Abbott Diagnostics

Becton Deckinson and Company

Roche

Qiagen

Siemens Healthcare

What the Report Offers

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both a global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Table of Contents

1. Introduction

  • 1.1 Study Deliverables
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions

2. Research Methodology

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Econometric Forecast Model
  • 2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

  • 5.1 Current Market Scenario
  • 5.2 Applications of Cervical Cancer diagnostics and therapeutics
  • 5.3 Technology Overview
  • 5.4 New Developments
  • 5.5 Industry Value-Chain Analysis
  • 5.6 Product Life-Cycle Analysis
  • 5.7 Product Benchmarking
  • 5.8 Investment Analysis
  • 5.8 Portera€™s Five Forces
    • 5.8.1 Bargaining Power of Suppliers
    • 5.8.2 Bargaining Power of Consumers
    • 5.8.3 Threat of New Entrants
    • 5.8.4 Threat of Substitute Products and Services
    • 5.8.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increasing prevalence of cervical cancer
    • 6.1.2 Increasing incidences of weakened immune system
    • 6.1.3 High use of cervical cancer diagnostic tests
    • 6.1.4 Long-term use of oral contraceptive pills
    • 6.1.5 Rapid spread of human papillomavirus (HPV) infection
    • 6.1.6 Favorable government initiatives and funding
    • 6.1.7 Lifestyle-related factors
  • 6.2 Market Restraints
    • 6.2.1 High cost of cancer therapeutics
    • 6.2.2 Changes in regulatory guidelines for cervical cancer screening
    • 6.2.3 Use of HPV vaccines
    • 6.2.4 Uncertain reimbursement rates
  • 6.3 Key Challenges
  • 6.4 Current Opportunities in the Market

7. Market Segmentation

  • 7.1 By End-Users
    • 7.1.1 Hospitals
    • 7.1.2 Clinical laboratories
    • 7.1.3 Healthcare centers
  • 7.2 Diagnostic tests
    • 7.2.1 Pap smear test
    • 7.2.2 HPV testing
    • 7.2.3 Colposcopy
    • 7.2.4 Loop Electrosurgical Excision Procedure
    • 7.2.5 Biopsy
    • 7.2.6 Endocervical Curettage
  • 7.3 Screening methods
    • 7.3.1 Molecular method
    • 7.3.2 Cytopathological method
    • 7.3.3 Physical method
  • 7.4 Therapy
    • 7.4.1 Surgery
    • 7.4.2 Radiation therapy
    • 7.4.3 Chemotherapy
    • 7.4.4 Vaccines
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.0 Introduction
      • 7.5.1.1 US
      • 7.5.1.2 Canada
      • 7.5.1.3 Rest of North America
    • 7.5.2 Europe
      • 7.5.2.0 Introduction
      • 7.5.2.1 France
      • 7.5.2.2 UK
      • 7.5.2.3 Germany
      • 7.5.2.4 Russia
      • 7.5.2.5 Italy
      • 7.5.2.6 Spain
      • 7.5.2.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.0 Introduction
      • 7.5.3.1 India
      • 7.5.3.2 China
      • 7.5.3.3 Japan
      • 7.5.3.4 Australia
      • 7.5.3.5 South Korea
      • 7.5.3.6 Rest of Asia-Pacific
    • 7.5.4 Middle East and Africa (MEA)
      • 7.5.4.1 Introduction
      • 7.5.4.2 UAE
      • 7.5.4.3 Saudi Arabia
      • 7.5.4.4 Israel
      • 7.5.4.5 Rest of the MEA
    • 7.5.5 Latin America
      • 7.5.5.1 Introduction
      • 7.5.5.2 Brazil
      • 7.5.5.1 Argentina
      • 7.5.5.4 Mexico
      • 7.5.5.5 Rest of Latin America

8. Competitive Landscape

  • 8.1 Merger and Acquisition Analysis
  • 8.2 Patent Analysis
  • 8.3 The Challengers

9. Company Profiles

  • 9.1 Abbott Diagnostics
  • 9.2 Becton Deckinson and Company
  • 9.3 Roche
  • 9.4 Qiagen
  • 9.5 Siemens Healthcare
  • 9.6 Dendreon Corporation
  • 9.7 Otsuka Pharmaceuticals
  • 9.8 Merck
  • 9.9 GlaxoSmithKline PLC
  • 9.10 Advaxis Immunotherapies
  • 9.11 Bionor Pharma

10. Analyst Outlook for Investment Opportunities

11. Future Outlook of the Market

Back to Top